---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-23-000010"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2023-01-13T23:59:59+00:00"
generated_at: "2026-06-20T15:14:44.597050+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio authorizes $50M stock repurchase plan; cash >$575M

## Summary
- Board authorized repurchase of up to $50M of common stock through Dec 31, 2023.
- Cash, equivalents, and investments >$575M as of Dec 31, 2022.
- Reiterates ~4 years of capital to execute R&D plan, excluding potential GSK royalties.
- Repurchases may occur in open market under Rule 10b5-1 and 10b-18; no obligation to buy.

## SEC filing metadata
- accession: 0001370053-23-000010
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2023-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000010/0001370053-23-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000010/anab-20230113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-23-000010
- JSON: https://secwatch.observer/filing/0001370053-23-000010.json
- Plain text: https://secwatch.observer/filing/0001370053-23-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.